Pharmaceutical manufacturers to develop drugs interfere in Russia

On Thursday, June 6 in Moscow hosted a press lunch Association InPharma. This organization includes 11 major international pharmaceutical companies operating in the territory of our country. During the discussion, the experts raised a number of issues relating to the protection of intellectual property development of drugs and discussed measures to create a favorable environment for investment in Russia.

InPharma

According to the executive director of the Association InPharma Vadim Kukava, currently the volume of research funding, aimed at creating innovative medicines, Russia is considerably inferior to Western countries. So, for the development of modern drugs have pharmaceutical manufacturers allocate about 60 million. Dollars a year, while the US laboratory receive about 40 billion. Dollars.

"The development of drugs is required, on average, up to $ 2 billion, and the necessary research takes a long time. Of 10,000 promising molecules only one becomes a drug and bring to market. That is why intellectual property plays a huge role in the innovative pharmaceutical companies, "- Kukava said.

His colleague added that the production of new drugs is possible only thanks to the protection of intellectual property rights, and without the relevant patents, the company would not last a day.

"The world practice in matters of registration of medicines - is the desire for an open process and dialogue. We believe that the Ministry of Health and Rospatent should increase the level of cooperation, and to ensure public access to information on the subjects to apply for registration of medicinal products and the names of the products ", - summed up the director of the Legal and Regulatory Affairs InPharma Nina Belozertseva.

For reference:
The Association includes 11 InPharma leading innovative pharmaceutical companies: AbbVie, Amgen, AstraZeneca, Bayer, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis and Pfizer. (READ MORE)

Industry News

Go back to the main page